These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review. Ploussard G; Daneshmand S; Efstathiou JA; Herr HW; James ND; Rödel CM; Shariat SF; Shipley WU; Sternberg CN; Thalmann GN; Kassouf W Eur Urol; 2014 Jul; 66(1):120-37. PubMed ID: 24613684 [TBL] [Abstract][Full Text] [Related]
5. Radical transurethral resection alone, robotic or partial cystectomy, or extended lymphadenectomy: can we select patients with muscle invasion for less or more surgery? Cha EK; Donahue TF; Bochner BH Urol Clin North Am; 2015 May; 42(2):189-99, viii. PubMed ID: 25882561 [TBL] [Abstract][Full Text] [Related]
6. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience. Giacalone NJ; Shipley WU; Clayman RH; Niemierko A; Drumm M; Heney NM; Michaelson MD; Lee RJ; Saylor PJ; Wszolek MF; Feldman AS; Dahl DM; Zietman AL; Efstathiou JA Eur Urol; 2017 Jun; 71(6):952-960. PubMed ID: 28081860 [TBL] [Abstract][Full Text] [Related]
7. Selective bladder preservation with curative intent for muscle-invasive bladder cancer: a contemporary review. Koga F; Kihara K Int J Urol; 2012 May; 19(5):388-401. PubMed ID: 22409269 [TBL] [Abstract][Full Text] [Related]
8. Bladder preservation in muscle-invasive bladder cancer: a comprehensive review. Hamad J; McCloskey H; Milowsky MI; Royce T; Smith A Int Braz J Urol; 2020; 46(2):169-184. PubMed ID: 31961624 [TBL] [Abstract][Full Text] [Related]